MaxCyte Inc expected to post a loss of 12 cents a share - Earnings Preview

MaxCyte

07/03/2025 20:19

MaxCyte Inc MXCT.OQ MXCT.O is expected to show a fall in quarterly revenue when it reports  results on March 11 for the period ending December 31 2024

The Rockville Maryland-based  company is expected to report a 49.0% decrease in revenue to $7.993 million from $15.67 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for MaxCyte Inc is for a loss of 12 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for MaxCyte Inc is $9.50​, above​ its last closing price of $3.51. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.12
-0.12
-0.11
Beat
10.8
Jun. 30 2024
-0.13
-0.13
-0.09
Beat
28.9
Mar. 31 2024
-0.13
-0.13
-0.09
Beat
30.8​
Dec. 31 2023
-0.07
-0.07
-0.05
Beat
30.6
​​Sep. 30 2023
-0.10
-0.10
-0.11
Missed
-7.8
Jun. 30 2023
-0.10
-0.10
-0.10
Met
-4.2​
Mar. 31 2023
-0.11
-0.11
-0.11
Met
1.8
Dec. 31 2022
-0.07
-0.05
Beat
28.6

This summary was machine generated March 7 at 20:19 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)